Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
February 10 2021 - 9:00PM
Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company
focused on discovering, developing, and commercializing gene
therapies to cure blindness diseases and developing a vaccine to
fight COVID-19, today announced that it has closed the previously
announced registered direct offering for the sale of an aggregate
of 3,000,000 shares of its common stock for gross proceeds of
approximately $23 million, prior to deducting placement agent’s
fees and other offering expenses payable by Ocugen.
H.C. Wainwright & Co. acted as the exclusive placement agent
for the offering.
Ocugen intends to use the net proceeds from the
offering for general corporate purposes, capital expenditures,
working capital and general and administrative expenses.
The shares of common stock described above were
offered pursuant to a “shelf” registration statement (File No.
333-237456) filed with the Securities and Exchange Commission
(“SEC”) on March 27, 2020 and declared effective on May 5, 2020.
Such shares of common stock were offered only by means of a
prospectus, including a prospectus supplement, forming a part of
the effective registration statement. A final prospectus supplement
and the accompanying prospectus relating to the offering of the
shares of common stock was filed with the SEC. Electronic copies of
the final prospectus supplement and the accompanying prospectus
relating to the offering of the shares of common stock may be
obtained on the SEC’s website at http://www.sec.gov or by
contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd
Floor, New York, NY 10022, by
e-mail: placements@hcwco.com or by telephone: (646)
975-6996.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company
focused on discovering, developing, and commercializing gene
therapies to cure blindness diseases and developing a vaccine to
fight COVID-19. Our breakthrough modifier gene therapy platform has
the potential to treat multiple retinal diseases with one drug –
“one to many,” and our novel biologic product candidate aims to
offer better therapy to patients with underserved diseases such as
wet age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please
visit www.ocugen.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
Such forward-looking statements within this press release include,
without limitation, the intended use of net proceeds from the
registered direct offering. We may, in some cases, use terms such
as “predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from our current
expectations, such as market and other conditions. These and other
risks and uncertainties are more fully described in our periodic
filings with the SEC, including the risk factors described in the
section entitled “Risk Factors” in the quarterly and annual reports
that we file with the SEC. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. Except as required by law, we assume no obligation to
update forward-looking statements contained in this press release
whether as a result of new information, future events or otherwise,
after the date of this press release.
Corporate Contact:Ocugen, Inc.Sanjay
SubramanianChief Financial Officer and Head of Corporate
DevelopmentIR@Ocugen.com
Media Contact:LaVoieHealthScienceEmmie
Twomblyetwombly@lavoiehealthscience.com+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024